Press Release from Merck & Co. Inc. Published: 11 January 11, Merck announced today that the new drug application (NDA) for the Company experimental JANUMET sustained release formulation of type 2 diabetes has been accepted for review by the U.S. Food and Drug Administration (FDA). The Company also is progressing as planned with regulatory filings in countries outside the United States.
Hives (Urticaria) & Angioedema Causes, Symptoms and Treatment